Abstract
Chronic lymphocytic leukemia (CLL), a clonal expansion of B CD5+ cells, is the most common type of adult leukemia in western countries. The accumulation of neoplastic B-cells is primarily caused by prolonged life-span of these cells due to deregulation of apoptosis, and only marginally due to a higher proliferation rate. In spite of numerous reports characterizing particular mechanisms of B-CLL cell apoptosis, still relatively little is known about the complex regulation of this process. Therefore, more detailed research is required to understand the complicated mechanisms and regulatory processes of apoptosis in neoplastic Blymphocytes.
Keywords: Apoptosis, B-cells, B-CLL, chronic lymphocytic leukemia, proliferation.
Graphical Abstract
Current Cancer Drug Targets
Title:Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Volume: 16 Issue: 8
Author(s): Monika Podhorecka, Arkadiusz Macheta, Maria Bozko, Andrzej Bozko, Nisar P. Malek and Przemyslaw Bozko
Affiliation:
Keywords: Apoptosis, B-cells, B-CLL, chronic lymphocytic leukemia, proliferation.
Abstract: Chronic lymphocytic leukemia (CLL), a clonal expansion of B CD5+ cells, is the most common type of adult leukemia in western countries. The accumulation of neoplastic B-cells is primarily caused by prolonged life-span of these cells due to deregulation of apoptosis, and only marginally due to a higher proliferation rate. In spite of numerous reports characterizing particular mechanisms of B-CLL cell apoptosis, still relatively little is known about the complex regulation of this process. Therefore, more detailed research is required to understand the complicated mechanisms and regulatory processes of apoptosis in neoplastic Blymphocytes.
Export Options
About this article
Cite this article as:
Podhorecka Monika, Macheta Arkadiusz, Bozko Maria, Bozko Andrzej, Malek P. Nisar and Bozko Przemyslaw, Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?, Current Cancer Drug Targets 2016; 16 (8) . https://dx.doi.org/10.2174/1568009616666160427103930
DOI https://dx.doi.org/10.2174/1568009616666160427103930 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets NK Cell Function in HIV-1 Infection
Current HIV Research Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets